Overview: Ataxia Type 2 CACNA1A Mutation TestIntroduction: The Ataxia Type 2 CACNA1A Mutation Test detects CACNA1A gene mutations linked to episodic ataxia, causing coordination loss or vertigo. Aligned with 2023 AAN guidelines, it uses PCR for high specificity, aiding in genetic screening. This test is critical for guiding diagnosis, treatment, and improving outcomes in molecular pathology for patients with suspected episodic ataxia type 2.
Other Names: CACNA1A Mutation Assay, Episodic Ataxia Type 2 Test.
FDA Status: Laboratory-developed test (LDT), meeting molecular pathology standards for diagnostic accuracy.
Historical Milestone: CACNA1A mutation testing began in the 1990s with ataxia research. PCR-based assays emerged in the 2000s, improving accuracy for genetic diagnosis.
Purpose: Diagnoses episodic ataxia type 2, guides treatment, and monitors CACNA1A mutations in patients with coordination loss or vertigo.
Test Parameters: 1. CACNA1A Mutation
Pretest Condition: No fasting required. Collect whole blood, buccal swab, or saliva at any time. Report symptoms like coordination loss or vertigo, and list family history of ataxia.
Specimen: 2-5 mL whole blood (EDTA), 1-2 buccal swabs (sterile swab), or 1-2 mL saliva (sterile container). Transport in a biohazard bag within 24 hours.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document coordination loss, vertigo, or family history of ataxia. Include current medications or prior genetic testing results.
Consent: Written consent required, detailing the tests purpose, diagnostic implications, and potential need for genetic counseling or therapy.
Procedural Considerations: Uses PCR to detect CACNA1A gene mutations. Results are available in 3-5 days, supporting clinical decisions.
Factors Affecting Result Accuracy: Contamination or low DNA yield can affect results. Rare mutations may require additional testing.
Clinical Significance: Positive mutation results confirm episodic ataxia type 2, prompting treatment or genetic counseling. Negative results may require further genetic testing.
Specialist Consultation: Consult a neurologist or geneticist for result interpretation.
Additional Supporting Tests: Neurological exam, EMG, or other ataxia gene testing to confirm diagnosis.
Test Limitations: False negatives may occur with rare mutations. Results require clinical correlation.
References: AAN Ataxia Guidelines, 2023; Neurology, Jen JC, 2022.
